Literature DB >> 6830178

Relapsing herpes simplex encephalitis following antiviral therapy.

L E Davis, L C McLaren.   

Abstract

Although treatment for herpes simplex virus (HSV) encephalitis with antiviral agents has improved survival, occasional patients experience unexplained clinical exacerbations. This report presents evidence that some relapses may occur from recurrent viral encephalitis. An adult male developed the classic symptoms of HSV encephalitis. The cerebrospinal fluid (CSF), electroencephalogram, and isotope brain scan suggested a localized encephalitis involving the left temporal lobe. The patient was treated for 10 days with high doses of cytosine arabinoside instead of the currently recommended adenine arabinoside. Progression of encephalitis stopped, and clinical recovery occurred. The HSV antibody titer increased eightfold. Fifty-four days after the initial encephalitis, the patient relapsed with a subacute progressive encephalitis involving the same brain area. The CSF demonstrated oligoclonal bands, elevated immunoglobulin G levels (100 mg/dl), and a high HSV antibody titer (1:8,192 by indirect hemagglutination test). From a left temporal lobe biopsy taken 74 days after onset of the initial encephalitis, herpes simplex virus type 1 was isolated. Without renewed antiviral drug therapy, the patient slowly recovered.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6830178     DOI: 10.1002/ana.410130215

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

1.  Subacute herpes simplex encephalitis presenting as relapsing encephalitis.

Authors:  Nils Peters; Gunther Fesl; Diethilde Theil; Ulrich Schüller; Tobias Birnbaum; Hartmut Brückmann; Soheyl Noachtar
Journal:  J Neurol       Date:  2010-01-23       Impact factor: 4.849

2.  Herpes simplex encephalitis with relapse.

Authors:  M G Pike; C R Kennedy; B G Neville; M Levin
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

Review 3.  Herpes simplex virus infections of the central nervous system. Encephalitis and neonatal herpes.

Authors:  R J Whitley
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

4.  HSV encephalitis-induced anti-NMDAR encephalitis in a 67-year-old woman: report of a case and review of the literature.

Authors:  Nicholas A Morris; Tamara B Kaplan; Jenny Linnoila; Tracey Cho
Journal:  J Neurovirol       Date:  2015-07-03       Impact factor: 2.643

5.  Intravenous infusion of cereport increases uptake and efficacy of acyclovir in herpes simplex virus-infected rat brains.

Authors:  D J Bidanset; L Placidi; R Rybak; J Palmer; J P Sommadossi; E R Kern
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

6.  Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults.

Authors:  B Sköldenberg; E Aurelius; A Hjalmarsson; F Sabri; M Forsgren; B Andersson; A Linde; O Strannegård; M Studahl; L Hagberg; L Rosengren
Journal:  J Neurol       Date:  2005-10-17       Impact factor: 4.849

7.  Twenty-five coregulated transcripts define a sterigmatocystin gene cluster in Aspergillus nidulans.

Authors:  D W Brown; J H Yu; H S Kelkar; M Fernandes; T C Nesbitt; N P Keller; T H Adams; T J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

8.  Retropharyngeal abscess.

Authors:  M Coulthard; D Isaacs
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

9.  Acyclovir treatment of herpes simplex encephalitis: experience in a district hospital.

Authors:  M C Gulliford; C P Chandrasekera; R A Cooper; R P Murphy
Journal:  Postgrad Med J       Date:  1987-12       Impact factor: 2.401

10.  Clinical Neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-Daspartate receptor antibodies are part of the problem.

Authors:  Romana Höftberger; Thaís Armangue; Frank Leypoldt; Francesc Graus; Josep Dalmau
Journal:  Clin Neuropathol       Date:  2013 Jul-Aug       Impact factor: 1.368

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.